Q8

• UNSPSC Description:

  Q8, an effective antiangiogenic drug, is a CysLt1 antagonist (IC50 of 4.9 μM). Q8 is sufficient to reduce cellular levels of NF-κB and calpain-2 and secreted levels of the proangiogenic proteins intercellular adhesion molecule-1, vascular cell adhesion protein-1, and VEGF[1].

• Target Antigen:

  Leukotriene Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/q8.html

• Smiles:

  OC1=CC=C(O)C=C1/C=C/C2=NC3=CC=CC=C3C=C2.Cl

• Molecular Weight:

  299.75

• References & Citations:

  [1]Clare T Butler, et al. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1541762-55-3